ReviewInternational journal of nanomedicine2026
Autophagy-Modulating Nanomedicine for Glioma: Delivery Barriers, Lysosomal Interactions, and a Flux-Resolved Translational Decision Framework.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioma nanomedicine is constrained by linked delivery and pharmacodynamic barriers: nanoscale systems must traverse heterogeneous blood-brain barrier (BBB) and blood-brain tumor barrier (BBTB) interfaces and achieve interpretable intracellular effects in tumor cells. Autophagy is a therapeutically relevant but context-dependent axis. However, similar changes in static autophagy markers, vesicular staining, or ultrastructure can reflect productive autophagy induction (ie, increased autophagic flux with successful lysosomal cargo degradation), blocked autophagosome-lysosome fusion, lysosomal dysfunction, or secondary cytotoxic stress. This ambiguity is amplified for nanomedicines because their physicochemical properties can independently shape autophagy-related readouts. Here, we frame autophagy-modulating nanomedicine for glioma as both a delivery challenge and a problem of translational interpretation, covering bioactive nanomaterials, nanocarriers, and multimodal platforms. We organize the field around an integrated framework linking BBB/BBTB access, intracellular trafficking, interpretation of autophagic flux, and translational readiness. We use structured evidence grading to distinguish flux-resolved, functionally validated mechanisms from marker-based or indirect inferences. This framework distinguishes mechanistically supported findings from provisional interpretations and defines the evidence required for translational progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.